Organization
Anaveon
4 clinical trials
2 abstracts
Clinical trial
A Phase 1/2 Study of ANV419 as Monotherapy or in Combination With Anti-PD-1 or Anti-CTLA-4 Antibody Following Anti-PD-1/Anti-PD-L1 Antibody Treatment in Patients With Unresectable or Metastatic Cutaneous Melanoma (OMNIA-1)Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
ANV419 First in Human Study Phase 1: Open-label, Dose Escalation Study of ANV419 as Single Agent and in Combination With Ipilimumab in Patients With Relapsed/Refractory Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase 1 Study of ANV419 as Monotherapy, and ANV419 in Combination With Daratumumab or With Lenalidomide Plus Low-Dose Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma (OMNIA-2)Status: Terminated, Estimated PCD: 2023-07-12
Abstract
OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma.Org: Anaveon, Institute of Medical Oncology, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Lillebaelt Hospital, University Hospital of Southern Denmark,
Abstract
OMNIA-1: A phase I/II study, an IL-2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti‑PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma.Org: Istituto Nazionale Tumori IRCCS Fondazione Pascale, Hospital Universitario 12 de Octubre, Charite-Universitaetsmedizin, Berlin, Germany, Chugai Pharmaceutical, Anaveon,
Clinical trial
A First-in-human, Open-label, Multicenter Phase I/II Study to Evaluate the Safety and Anti-tumor Activity of ANV600 as Single Agent and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1)Status: Not yet recruiting, Estimated PCD: 2027-10-01